Lunit Appoints SBVA CEO Lee Jun-pyo as New Outside Director at General Meeting

Junpyo Lee, CEO of SBVA, Appointed as Outside Director
Garheng Kong Reappointed as Director

Seo Beom-seok, CEO of Lunit (right), and Ken Nesmith, CBO of Lunit (left), are giving greetings at the 12th Annual General Meeting of Shareholders held on the 27th at the KAMCO Yangjae Tower in Gangnam-gu, Seoul. Photo by Lunit

Medical artificial intelligence (AI) company Lunit held its 12th regular general meeting of shareholders on the 27th at the Kamco Yangjae Tower in Gangnam-gu, Seoul, and announced that all seven agenda items were approved as originally proposed.

At the general meeting, key agenda items including ▲the appointment of CEO Junpyo Lee of SoftBank Ventures Asia (SBVA) as a new outside director and audit committee member ▲the reappointment of outside director Garheng Kong ▲approval of the 12th financial statements ▲approval of the director remuneration limit were all passed.

At the meeting, Lunit appointed SBVA CEO Junpyo Lee as an outside director to provide new momentum for its global growth strategy. Lee, an outside director with expertise in AI and information and communication technology (ICT), has built a successful investment portfolio in global AI companies, and based on this experience, is expected to play a key role in Lunit’s technological innovation and global market expansion.

Additionally, Lunit reappointed Garheng Kong, founder of HealthQuest Capital, who has served as an outside director since 2022. Director Kong has played an important role in building Lunit’s global business network and will continue to contribute to the establishment of global sales strategies going forward.

In particular, through this general meeting, Lunit reexamined its financial strategy reflecting the challenges of the rapidly changing global economic environment and presented a concrete roadmap to achieve successful business outcomes.

Ken Nesmith, Chief Business Officer (CBO) overseeing Lunit SCOPE’s global business, explained in the announcement that, based on the technological differentiation of Lunit SCOPE, in addition to the partnership officially announced last year with AstraZeneca, they are currently discussing new collaborations with multiple global big pharma companies.

Seobeom Seok, CEO of Lunit, said, “The global investment capabilities and deep insights into the AI industry of outside director Junpyo Lee will provide a solid foundation for Lunit’s global market entry strategy. We will lead the global medical AI industry through balanced growth of ‘Lunit Insight,’ which continues stable revenue growth, and ‘Lunit SCOPE,’ which is preparing for collaboration with global big pharma.”